UBS Group’s Acadia Pharmaceuticals ACAD Stock Holding History

UBS Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-9,000	Closed	-$210K	–	10163
2021 Q4	$210K	Hold	9,000	–	–	﹤0.01%	5641
2021 Q3	$149K	Hold	9,000	–	–	﹤0.01%	5541
2021 Q2	$220K	Hold	9,000	–	–	﹤0.01%	5270
2021 Q1	$232K	Buy	+9,000	New	+$396K	﹤0.01%	5377
2018 Q1	–	Sell	-1,600	Closed	-$48K	–	7764
2017 Q4	$48K	Buy	+1,600	New	+$51.2K	﹤0.01%	5863
2015 Q2	–	Sell	-100	Closed	-$3K	–	8445
2015 Q1	$3K	Sell	100 -1,000	-91%	-$34.4K	﹤0.01%	8308
2014 Q4	$35K	Buy	+1,100	New	+$31.2K	﹤0.01%	6925

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group's ACAD Position: Q2 2026 in Review

UBS Group increased its Acadia Pharmaceuticals (ACAD) stake by 2.6% in Q2 2026, buying an estimated $253K and bringing the position to 460,053 shares worth $11.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3282.

UBS Group first reported a position in ACAD in Q4 2014 and has held it in 47 quarters since. The position peaked at $22.8M in Q4 2024. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

UBS Group held 460,053 shares of Acadia Pharmaceuticals worth $11.6M as of Q2 2026.
UBS Group bought 11,504 Acadia Pharmaceuticals shares in Q2 2026, an estimated $253K.
Acadia Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3282 holding.
UBS Group first reported a position in Acadia Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
UBS Group's Acadia Pharmaceuticals position peaked at $22.8M in Q4 2024.
353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.